Fresenius SE & Co KGaA (FRA:FRE) PT Set at €47.00 by UBS Group

UBS Group set a €47.00 ($52.81) price target on Fresenius SE & Co KGaA (FRA:FRE) in a report published on Friday, Borsen Zeitung reports. The brokerage currently has a neutral rating on the stock.

Other research analysts also recently issued reports about the company. Kepler Capital Markets set a €62.00 ($69.66) target price on Fresenius SE & Co KGaA and gave the company a buy rating in a research note on Friday, March 20th. Morgan Stanley set a €48.00 ($53.93) target price on Fresenius SE & Co KGaA and gave the company a buy rating in a research note on Wednesday, May 20th. Deutsche Bank set a €57.00 ($64.04) target price on Fresenius SE & Co KGaA and gave the company a buy rating in a research note on Monday, June 8th. Jefferies Financial Group set a €37.00 ($41.57) target price on Fresenius SE & Co KGaA and gave the company a neutral rating in a research note on Wednesday, May 6th. Finally, Credit Suisse Group set a €50.00 ($56.18) target price on Fresenius SE & Co KGaA and gave the company a neutral rating in a research note on Friday, May 22nd. Six analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Fresenius SE & Co KGaA has a consensus rating of Buy and an average target price of €51.85 ($58.26).

FRE opened at €44.21 ($49.67) on Friday. The business’s 50 day moving average is €42.86 and its two-hundred day moving average is €43.21. Fresenius SE & Co KGaA has a 52 week low of €60.16 ($67.60) and a 52 week high of €80.00 ($89.89).

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.

See Also: FinTech

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.